AKT1 and triple-negative breast carcinoma: NOB can inhibit the activity of ERK1/2, causing the cells to be arrested at the G0/G1 phase, downregulate cyclin-D1 and upregulate p21, reduce the expression of Bcl-xL, inducing apoptosis, and inhibit the activities of AKT and downstream mTOR, thereby exerting an anti-triple-negative breast cancer cell effect [29].